N. Anthony Coles - Feb 9, 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc. (CERE)

Role
CEO and Chairperson, Director
Signature
/s/ Mark Bodenrader, as Attorney-in-Fact
Stock symbol
CERE
Transactions as of
Feb 9, 2022
Transactions value $
$0
Form type
4
Date filed
2/11/2022, 05:45 PM
Previous filing
Jan 5, 2022
Next filing
Sep 8, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Award $0 +426K $0.00 426K Feb 9, 2022 Common Stock 426K $30.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on February 9, 2023, with the remainder vesting in thirty-six (36) monthly installments thereafter.